Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, TET2 mutations were identified in 32 of 33 (97%) cases with IDH2<sup>R172</sup> and/or RHOA<sup>G17V</sup> mutations whereas only 55% of angioimmunoblastic T-cell lymphoma cases wild-type for these two genes carried TET2 mutations (p = 0.0022).
|
30952970 |
2019 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent sequencing studies have clarified the recurrent mutations in ras homology family member A (RHOA) and in genes encoding epigenetic regulators, tet methyl cytosine dioxygenase 2 (TET2), DNA methyl transferase 3 alpha (DNMT3A) and isocitrate dehydrogenase 2, mitochondrial (IDH2), as well as those related to the T-cell receptor signaling pathway in AITL.
|
28889481 |
2018 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recent genetic analysis has identified frequent mutations in ten-eleven translocation 2 (TET2), DNA methyltransferase 3A (DNMT3A), isocitrate dehydrogenase 2 (IDH2) and ras homolog family member A (RHOA) in nodal T-cell lymphomas, including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified.
|
28157189 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, TET2-mutated haematopoietic precursor cells in AITL patients not only give rise to the T-cell lymphoma but also generate a large population of mutated mature B cells.
|
28337768 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.
|
27353473 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we have demonstrated that TET2 loss and RhoAG17V expression in mature murine T cells cooperatively cause abnormal CD4+ T cell proliferation and differentiation by perturbing FoxO1 gene expression, phosphorylation, and subcellular localization, an abnormality that is also detected in human primary AITL tumor samples.
|
28691928 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we investigated the impact of TET2 mutations on methylation of BCL6 locus in human AITL/PTCL samples.
|
27921272 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results confirm that TET2 mutation is an early event in the majority of AITL cases, and that the driving molecular anomalies are not restricted to the T lineage tumour cells.
|
28543514 |
2017 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genome wide sequencing studies have dissected the repertoire of the genetic alterations driving AITL uncovering a highly recurrent Gly17Val somatic mutation in the small GTPase RHOA and major role for mutations in epigenetic regulators, such as TET2, DNMT3A and IDH2, and signaling factors (e.g., FYN and CD28).
|
27177312 |
2016 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, mutations in TET2 and other epigenetic modifiers as well as RHOA have been identified in these diseases, particularly in angioimmunoblastic T-cell lymphoma (AITL).
|
26719098 |
2016 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These analyses identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 (18%) PTCL, not otherwise specified (PTCL-NOS) samples.
|
24413734 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
TET2 loss-of-function mutations are highly frequent in subtypes of T-cell lymphoma that harbor follicular helper T (Tfh)-cell-like features, such as angioimmunoblastic T-cell lymphoma (30-83%) or peripheral T-cell lymphoma, not otherwise specified (10-49%), as well as myeloid malignancies.
|
25501021 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
DNMT3A mutations occurred in 28 (33%) AITLs; 100% of these also harbored TET2 mutations (P < .0001).
|
24345752 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that impaired RHOA function in cooperation with preceding loss of TET2 function contributes to AITL-specific pathogenesis.
|
24413737 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
CTD_human |
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.
|
24413737 |
2014 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
Biomarker
|
disease |
BEFREE |
This is the second common genetic lesion identified in AITL after TET2 and extends the number of neoplastic diseases where IDH1 and IDH2 mutations may play a role.
|
22215888 |
2012 |
Angioimmunoblastic Lymphadenopathy
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among PTCL-NOS, a heterogeneous group of lymphoma-comprising cases likely to derive from Th follicular (T(FH)) cells similarly to AITL, TET2 mutations were more frequent when PTCL-NOS expressed T(FH) markers and/or had features reminiscent of AITL (58% vs 24%, P = .01).
|
22760778 |
2012 |